论文部分内容阅读
日本三家公司即北里研究所、绿十字会公司以及血化所,由“厚生省”批准生产乙肝疫苗,于1985年9月前后,投放市场并使用。他们生产疫苗来源为adr亚型、e抗原阴性血清,超速离心纯化60度10小时及福尔马林灭活,含40ng表面抗原蛋白,含一定量铝佐剂.供成人用为0.5毫升,婴儿用为0.25毫升.有2000人注射了各种疫苗,抗HBs有85%阳转,青幼年效应最好,女性较男性有8%的差别。抗HBs最高峰在第三次注射后,滴度亦最高,经过三年观察全部保持阳性,滴度有所下降。预防乙肝传染的主要部分是阻止母婴传播,通
Japan’s three companies namely North Institute, Green Cross Society and the Institute of blood, approved by the “Ministry of Health,” the production of hepatitis B vaccine, in September 1985 around the launch and use. They produced vaccine sources of adr subtype, e antigen-negative serum, ultracentrifugation purified 60 degrees 10 hours and formalin inactivation, containing 40ng surface antigen protein, containing an amount of aluminum adjuvant for adults with 0.5 ml, infants Used for 0.25 ml. 2000 people were injected with various vaccines, anti-HBs 85% of the male, the best effect of adolescent, women than men 8% difference. After the third injection, the highest peak of anti-HBs also had the highest titer. After three years of observation, all remained positive, and the titer declined. The main part of the prevention of hepatitis B infection is to prevent mother-to-child transmission